FORMULATION : EMERGING MARKETS
More Reyra operates across approximately 70 countries globally, with a strong emphasis on the USA, Asia, and Africa. Additionally, we have a joint venture in Japan.
More Reyra employs a strategic go-to-market approach, leveraging partnerships and a distributor model tailored to diverse market dynamics. This enables us to effectively deliver our specialized product portfolio on a global scale.
More Reyra specialize in providing a range of immunosuppressant final products to global markets, and with the support of strong product development and regulatory teams, we assist our partners in navigating various regulatory landscapes worldwide. Emphasizing cGMP compliance, our facilities undergo rigorous inspections by the USFDA and other global regulatory authorities. More Reyra Trading Company is committed to delivering high-quality final products at competitive prices to meet the needs of patients worldwide.
With a strong pipeline of products, More Reyra aims to expand further in global markets through enhanced market penetration and a carefully calibrated strategy
| Sr. No | Brand Name | Generic Name | Dosage | Strength |
|---|---|---|---|---|
| 1 | Mofecon C | Mycophenolate Mofetil | Capsules | 250mg |
| 2 | Mofecon 500 | Mycophenolate Mofetil | Tablets | 500mg |
| 3 | Mofecon OS | Mycophenolate Mofetil | Suspension | 1g/ml |
| 4 | Mofecon S 180 | Mycophenolate Sodium | Tablets | 180mg |
| 5 | Mofecon S 360 | Mycophenolate Sodium | Tablets | 360mg |
| 6 | Tacrolimus 0.5 | Tacrolimus | Capsules | 0.5mg |
| 7 | Tacrolimus 1 | Tacrolimus | Capsules | 1mg |
| 8 | Tacrolimus 5 | Tacrolimus | Capsules | 5mg |